ArticleJournal of ovarian research2025
Age-stratified analysis of euploidy rates in Progestin-Primed Ovarian Stimulation (PPOS) utilizing micronized progesterone or dydrogesterone versus GnRH analogues.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposesThis study aims to analyze the euploidy rates of PPOS utilizing micronized progesterone and dydrogesterone in comparison to conventional controlled ovarian stimulation (COS) protocols in pre-implantation genetic testing for aneuploidy (PGT-A) cycles stratified by age cohorts.
methodsThis was a retrospective study including 2897 PGT-A cycles from a single reproductive medicine center. Study groups were categorized by different COS protocols, including PPOS (micronized progesterone), PPOS (dydrogesterone), GnRH-agonist, or GnRH-antagonist, and further sub-grouped into < 35 years, 35-37 years, 38-40 years, and > 40 years. Data about baseline characteristics, protocols and embryonic outcomes were analyzed. Multivariate regression analysis and adjustment by inverse probability of treatment weighting (IPTW) were performed to investigate the correlation between COS protocols and euploidy rate per biopsied blastocyst.
resultsBefore stratified analysis and adjustment, the PPOS (dydrogesterone) group had significantly higher age, lower AMH level and fewer AFC than the PPOS (micronized progesterone), the GnRH-a and GnRH-Ant groups. Euploidy rate per COC, per MII oocyte and per biopsied blastocyst were lowest in the PPOS (dydrogesterone) group, followed by the PPOS (micronized progesterone) group. In subgroup analysis, the euploidy rate showed great disparity in different age groups and declined sharply every three years. All COS protocols were statistically comparable with respect to euploidy rate across all age cohorts. Regression analysis and IPTW adjustment revealed age as the sole factor affecting euploidy rates, with ovarian stimulation protocols showing no association.
conclusionsPPOS protocols using micronized progesterone or dydrogesterone were statistically comparable with conventional COS regimens in euploidy rates across all different age groups. Considering the significant impact of age, the necessity of refined age stratification for a more rigorous discussion about the aneuploidy risk of different COS protocols was emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.